Acetaminophen/paracetamol

DRUG4 trials

Sponsors

Merck Sharp & Dohme LLC, GlaxoSmithKline, Hoffmann-La Roche

Conditions

Cerebrovascular AccidentHeart DiseaseLupus NephritisMigraine DisordersPemphigusPeripheral Vascular DiseasesSystemic Lupus ErythematosusTIA (Transient Ischemic Attack)

Phase 2

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

RecruitingNCT05039619

Hoffmann-La RocheLupus Nephritis

Start: 2022-05-12End: 2030-06-14Target: 40Updated: 2026-04-03

Phase 3

Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)

CompletedNCT00662818

Merck Sharp & Dohme LLCCerebrovascular Accident, Heart Disease, Migraine Disorders +3

Start: 2008-03-17End: 2009-09-02Updated: 2018-10-19

Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

TerminatedNCT02613910

GlaxoSmithKlinePemphigus

Start: 2015-12-23End: 2016-03-23Updated: 2017-06-14

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

Active, not recruitingNCT04963296

Hoffmann-La RocheSystemic Lupus Erythematosus

Start: 2021-10-26End: 2028-03-14Updated: 2026-01-07

Related Papers

Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus.

2026-03-06

Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas

BMJ Open2024-07-0119 citations